Application of Serum Thymidine Kinase-1 in Cancer Risk Detection in Healthy Population

The purpose of this study was to evaluate the application of serum thymidine kinase 1 (STK1) in cancer risk detection in health general investigation. Using the method of dot-blot immunofluorescence enhancement, the data of STK1 of 12600 people were selected, and were carried out simultaneously with routine physical examination items. The results showed that the positive rate of STK1 (STK1> 2 pmol/L) was 2.10% with 2 pmol/L as the threshold, and the positive rates of male and female were 2.01% and 2.19%, respectively. There was no significant difference between male and female (χ2 = 0.46, P > 0.05). Compared with other age groups, both male and female between 40–59 years old had the highest detection rate in the age group of STK1 elevation, and twelve cases of malignant tumors were detected in the group of STK1 elevation, accounting for 4.55%. Compared with the normal group, it has significant significance. In the cases of benign tumors/cell dysplasia, 2194 cases detected were in normal group (17.78%) and 120 cases were in elevated group (45.45%). There was significant difference between normal group and elevated group (χ2 = 74.44, P < 0.01). There was no significant difference between the normal group and the elevated group in inflammatory, viral, fatty liver disease, other diseases and no special clinical conditions (P > 0.05). In the screening of cancer risk of general health investigation, STK1 can be applied to truly evaluate the abnormal proliferation of cells in vivo, and to screen a variety of tumors. It is suitable for early cancer risk screening of physical examination population.